



# Budget 2023-24

This information is accurate as of 9 May 2023.

## Pharmaceutical Benefits Scheme New and Amended Listings

This measure lists new medicines on the Pharmaceutical Benefits Scheme (PBS) and expands access to others.

This will provide for better treatment and improved health of Australians.

These changes are based on recommendations to the government from the independent Pharmaceutical Benefits Advisory Committee.

The PBS provides subsidised access to medicines to:

- Australian residents
- overseas visitors from countries under Reciprocal Health Care Agreements.

The PBS is managed by the Department of Health and Aged Care and administered by Services Australia.

You can learn more about [the PBS](#) on its website.

### New and amended listings from 1 November 2022

- Burosumab (Crysvita) for the treatment of X-linked hypophosphataemia
- Molnupiravir (Lagevrio), nirmatrelvir and nitonavir (Paxlovid) for the treatment of COVID-19 infection.

### New and amended listings from 1 December 2022

- Evolocumab (Repatha) for the treatment of hypercholesterolaemia
- Vericiguat (Verquvo) for the treatment of chronic heart failure
- Pegcetacoplan (Empaveli) for the treatment of paroxysmal nocturnal haemoglobinuria.

### New and amended listings from 1 January 2023

- Faricimab (Vabysmo) for the treatment of diabetic macular oedema and neovascular age-related macular degeneration
- Romiplostim (Nplate) and eltrombopag (Revolade) for the treatment of immune thrombocytopenia
- Daratumumab (Darzalex SC) for the treatment of newly diagnosed systemic light-chain AL amyloidosis

- Beclometasone with formoterol and glycopyrronium (Trimbow) for the maintenance therapy of severe asthma.

### **New and amended listings from 1 April 2023**

- Mepolizumab (Nucala) for the treatment of chronic rhinosinusitis with nasal polyps
- Nivolumab (Opdivo) for the adjuvant treatment of patients with oesophageal cancer or gastroesophageal junction cancer
- Sapropterin (Kuvan) for the treatment of adult patients with hyperphenylalaninaemia due to phenylketonuria.

### **New and amended listings from 1 May 2023**

- Asciminib (Scemblix) for the treatment of chronic myeloid leukaemia
- Ozanimod (Zeposia) for the treatment of moderate to severe ulcerative colitis
- Upadacitinib (Rinvoq) for the treatment of moderate to severe ulcerative colitis
- Ustekinumab (Stelara) for the treatment of moderate to severe ulcerative colitis
- Elexacaftor, tezacaftor, ivacaftor and ivacaftor (Trikafta) for the treatment of cystic fibrosis in patients who are aged 6 to 11 and who have at least one F508del mutation on the cystic fibrosis transmembrane conductance regulator gene.

### **New and amended listings from 1 June 2023**

Apalutamide (Eryand) for the treatment of metastatic hormone sensitive prostate cancer.

This measure is not subject to legislation passing.

### **Who this measure affects**

This measure affects Australian residents and overseas visitors from countries under Reciprocal Health Care Agreements.

### **When this starts and finishes**

The new and amended PBS listings are effective from dates stated above and are ongoing.